Congenital hepatic fibrosis (CHF) is a rare inherited liver disease present from birth, caused by abnormal development of the bile ducts during fetal life. Unlike the fibrosis that follows years of alcohol abuse or viral hepatitis, CHF is baked into the liver’s architecture before a person ever takes a breath. The condition was first formally described in 1961, and only a few hundred cases have been documented in the medical literature since then, though the true number of affected people is almost certainly higher because mild cases can go undiagnosed for decades.1PubMed Central. Congenital hepatic fibrosis: case report and review of literature What makes CHF particularly tricky is that it rarely exists in isolation. It tends to show up alongside kidney disease, other biliary abnormalities, and sometimes conditions affecting the eyes or brain, which means understanding it requires looking well beyond the liver.
What Goes Wrong During Development
During normal fetal development, the bile ducts inside the liver form through a temporary structure called the ductal plate. Think of it as a sleeve of cells that wraps around the developing portal veins and gradually reshapes itself into the network of small tubes that will carry bile. In CHF, this remodeling process stalls or goes awry. The ductal plate fails to mature properly, leaving behind malformed bile duct remnants embedded in excess fibrous tissue.2PubMed. An update on ductal plate malformations and fibropolycystic diseases of the liver This same developmental glitch, called ductal plate malformation, sits at the root of several related conditions, including Caroli disease (where the larger bile ducts become abnormally dilated), von Meyenburg complexes (clusters of tiny malformed bile ducts), and the liver cysts seen in polycystic kidney diseases.
The proteins involved in this process are linked to structures called cilia, which are tiny hair-like projections on the surface of cells lining the bile ducts and kidney tubules. These cilia act as sensors, helping cells respond to their environment. When the genes encoding these ciliary proteins carry mutations, both the liver and kidneys can develop abnormally. The gene most commonly implicated in CHF is PKHD1, the same gene responsible for autosomal recessive polycystic kidney disease (ARPKD).3Cell Press (Trends in Molecular Medicine). Unraveling the molecular players in hepatic cystogenesis This shared genetic origin explains why CHF and kidney disease so often travel together.
How CHF Looks Under the Microscope
A liver biopsy remains the gold standard for diagnosing CHF. Under the microscope, the hallmark findings form a recognizable triad: abnormal bile duct profiles (misshapen and excessive small ducts that never properly formed), underdeveloped portal vein branches, and bands of fibrosis expanding the portal tracts.4PubMed Central. Congenital hepatic fibrosis and its mimics: a clinicopathologic study of 19 cases at a single institution All confirmed cases in a 19-patient study at a single institution showed this classic combination. Importantly, the fibrosis in CHF is not the same as cirrhosis. The liver’s basic functional units remain largely intact, which is why liver function tests can stay near-normal even when the structural damage is advanced. The fibrosis is concentrated around the portal areas rather than disrupting the entire liver architecture the way cirrhosis does.
Even experienced pathologists can find CHF tricky to distinguish from other fibrotic liver diseases, particularly in adults who lack an obvious history of childhood liver problems. In one series, all adult-diagnosed cases showed the characteristic abnormal bile ducts set within fibrotic portal tissue, but arriving at the correct diagnosis often required clinicians to specifically consider CHF as a possibility rather than defaulting to more common causes of liver fibrosis.5PubMed. Diagnosis of Congenital Hepatic Fibrosis in Adulthood
What Patients Actually Experience
The clinical picture of CHF varies enormously. Some people have no symptoms at all until a routine blood test or imaging study reveals something unexpected. Others develop serious complications in childhood. The range runs from completely silent disease to acute liver decompensation.6PubMed Central. Congenital hepatic fibrosis: case report and review of literature
The most common and most dangerous manifestation is portal hypertension, which is high blood pressure in the veins that drain the intestines and spleen into the liver. Because CHF distorts the liver’s internal vasculature, blood has trouble flowing through the organ normally. The resulting backup of pressure causes the spleen to enlarge and forces blood to find alternative routes, leading to swollen veins (varices) in the esophagus and stomach. These varices can rupture and bleed, sometimes severely. In a study of siblings with biopsy-confirmed CHF, both children had hepatosplenomegaly and portal hypertension with esophageal varices, and one experienced repeated episodes of vomiting blood.7PubMed Central. A Family of Congenital Hepatic Fibrosis and Atypical Retinitis Pigmentosa
A large study of children with CHF found that significant portal hypertension with esophageal varices was present in roughly 86% of cases.8PubMed. Phenotypic variation and long-term outcome in children with congenital hepatic fibrosis That figure is striking and underscores why gastrointestinal bleeding is the complication clinicians worry about most. Yet because actual liver cell function is often preserved, these patients do not look or feel “sick” the way someone with advanced cirrhosis might. Their skin color is normal, their thinking is clear, and their blood clotting works fine, right up until a variceal bleed announces the underlying problem.
Diagnosis in Adults and Delayed Recognition
Although CHF is present from birth, a significant number of people are not diagnosed until adulthood. This happens for a straightforward reason: if someone’s portal hypertension develops slowly and their varices do not bleed, there may be no dramatic event to trigger investigation. Adults sometimes come to attention through incidental findings on imaging, through investigation of an enlarged spleen found on physical exam, or through mildly abnormal liver tests that do not fit a clear pattern.
In one case series, three adult patients presented with mildly to moderately elevated liver enzymes and bilirubin along with progressive spleen enlargement. One woman was initially misdiagnosed with a pregnancy-related liver condition, but her abnormalities persisted after delivery and failed to improve with standard treatment, eventually prompting a liver biopsy that revealed CHF.9PubMed Central. Congenital Hepatic Fibrosis in Children and Adults: Clinical Manifestations, Management, and Outcome—Case Series and Literature Review Stories like these illustrate a recurring theme: CHF enters the differential diagnosis only when more common liver diseases have been ruled out, and sometimes only after years of being mislabeled.
Imaging can support the diagnosis. MRI of the abdomen may reveal an abnormal liver contour, signs of portal hypertension, and elevated liver stiffness consistent with fibrosis.10Frontiers in Gastroenterology. Congenital hepatic fibrosis in an adult female combined with Von Meyenburg complex and autosomal dominant polycystic kidney disease: a case report But imaging alone cannot confirm CHF. The structural details seen on biopsy remain essential because no scan can reliably distinguish the specific pattern of ductal plate malformation from other forms of liver fibrosis.
The Kidney Connection
CHF and kidney disease are so intertwined that discussing one without the other gives an incomplete picture. The most important overlap is with ARPKD, the most common genetic ciliopathy of childhood, which is characterized by both congenital hepatic fibrosis and progressive cystic degeneration of the kidneys.11PubMed Central. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease Estimated to occur in about 1 in 20,000 live births, ARPKD means that CHF is part of the package for every affected child, though the severity of liver and kidney involvement can vary independently.12PubMed Central. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference Some children have severe kidney disease but manageable liver findings; others have the reverse.
CHF can also appear alongside autosomal dominant polycystic kidney disease (ADPKD), a more common but typically adult-onset form of cystic kidney disease.13PubMed Central. Congenital hepatic fibrosis: case report and review of literature The clinical presentations span a wide spectrum, and the balance between kidney and liver symptoms varies from one person to another even within the same family.14PubMed Central. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF) This variability is one of the things that makes caring for these patients complicated. A nephrologist focused on declining kidney function might not be closely monitoring the liver, and vice versa.
Among children with CHF and Caroli syndrome (the combination of CHF with dilated bile ducts), those with Caroli syndrome had a notably higher rate of developing significant chronic kidney disease compared to those with CHF alone, with 85% versus 42% progressing to advanced kidney impairment in one longitudinal study.15PubMed. Phenotypic variation and long-term outcome in children with congenital hepatic fibrosis This finding matters for families navigating the condition, because the presence of dilated bile ducts signals a more aggressive trajectory for the kidneys, not just for the liver.
Syndromic Associations Beyond the Liver and Kidneys
Because the underlying defect involves ciliary proteins that function in many organ systems, CHF can appear as one feature of broader genetic syndromes that affect the brain, eyes, and limbs. Joubert syndrome is a primarily autosomal recessive condition characterized by a distinctive brain malformation (visible on MRI as the “molar tooth sign”), along with low muscle tone, coordination problems, and intellectual disability. Variable features include retinal degeneration, cystic kidney disease, liver fibrosis, and extra fingers or toes.16PubMed Central. Joubert syndrome: insights into brain development, cilium biology, and complex disease
A specific subtype known as COACH syndrome combines the brain malformation of Joubert syndrome with developmental delay, coordination difficulties, an eye abnormality called a coloboma, and hepatic fibrosis. Mutations in at least three genes (MKS3, CC2D2A, and RPGRIP1L) have been identified as causes.17Journal of Medical Genetics. Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis) Even conditions like retinitis pigmentosa, a progressive loss of night and peripheral vision, have been reported in families with CHF, hinting at the broad reach of ciliary dysfunction across the body.18PubMed Central. A Family of Congenital Hepatic Fibrosis and Atypical Retinitis Pigmentosa
For clinicians, recognizing these associations is practical, not academic. A child diagnosed with CHF should be screened for kidney problems and eye abnormalities, and a child with Joubert syndrome should have their liver evaluated. The connections are not coincidental; they flow from the same genetic roots.
Complications That Change the Game
Two complications of CHF deserve specific attention because they shift the management conversation: recurrent cholangitis and, much more rarely, cancer.
Cholangitis is an infection of the bile ducts. In CHF and related ductal plate malformations, malformed and sometimes dilated bile ducts create pockets where bile stagnates, giving bacteria a foothold. These infections tend to recur and can involve drug-resistant bacteria, making antibiotic selection genuinely difficult.19Livers. Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature In the study comparing CHF and Caroli syndrome, cholangitis developed in about a quarter of the children, and it was significantly more common in those with dilated bile ducts.20PubMed. Phenotypic variation and long-term outcome in children with congenital hepatic fibrosis For patients who have received a kidney transplant for ARPKD but still carry their native liver, dilated bile ducts complicated by sepsis represent a real threat to survival. In one analysis, a third of those who died from biliary complications had no prior warning episodes of infection.21American Journal of Transplantation. Morbidity from Congenital Hepatic Fibrosis after Renal Transplantation for Autosomal Recessive Polycystic Kidney Disease
Bile duct cancer (cholangiocarcinoma) is rare in CHF but has been reported. A survey of the literature suggests that malignant transformation of the abnormal bile ducts occurs with increased frequency in congenital biliary dilatation overall, though it appears to be a particular risk mainly in patients who survive long enough for the cumulative exposure to chronic inflammation to matter.22PubMed. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. One autopsy report documented the fourth known case of cholangiocarcinoma arising within a CHF liver, with evidence that the cancer developed through a sequence of abnormal changes in the malformed bile duct lining.23PubMed. Intrahepatic cholangiocarcinoma arising in congenital hepatic fibrosis: report of an autopsy case While the absolute risk remains low, the possibility argues for long-term surveillance in older CHF patients, particularly those with dilated ducts.
Managing Portal Hypertension and Variceal Bleeding
Because portal hypertension drives most of the serious symptoms, much of CHF management centers on preventing and treating variceal bleeding. Endoscopic variceal ligation, a procedure in which rubber bands are placed around swollen veins in the esophagus to make them shrink, is the frontline approach. Many patients need repeated sessions. For those who continue to bleed despite endoscopy, surgical shunts can reroute blood flow to relieve pressure in the portal system. In a small series, patients who underwent a distal splenorenal shunt after frequent ligation sessions saw their variceal bleeding essentially stop during follow-up.24Hepatology Research. Ductal plate malformation and congenital hepatic fibrosis: Clinical and histological findings in four patients
The important thing to understand is that controlling portal hypertension in CHF is a long game, not a cure. The structural abnormality in the liver is permanent. The goal is to manage the downstream consequences well enough that patients live full, functional lives, which many do, often for decades, with intact liver function that would be the envy of anyone with comparable fibrosis from acquired liver disease.
When Transplantation Enters the Picture
Liver transplantation is not routine for CHF. The liver cells themselves work fine in most patients, and transplant carries its own lifelong burdens. But when portal hypertension becomes unmanageable, when recurrent cholangitis threatens life, or when both the liver and kidneys are failing (as often happens in ARPKD), transplantation becomes a serious consideration.
Combined liver-kidney transplantation has been performed in children with ARPKD and severe CHF with generally favorable results. In one series, all patients survived the procedure, with liver graft survival at 72% and kidney graft survival at 88%. Kidney function stabilized at reasonable levels, and the children showed significant improvements in growth after transplant.25PubMed. Combined liver-kidney transplantation for children with autosomal recessive polycystic kidney disease (ARPKD): indication and outcome Deciding when to proceed remains one of the harder calls in pediatric hepatology. The degree of portal hypertension, imaging findings over time, and liver biopsy results all feed into the decision.
An underappreciated scenario involves children who receive a kidney transplant for ARPKD but retain their native liver. These patients are immunosuppressed (to prevent kidney rejection), and their abnormal bile ducts remain vulnerable to infection. The evidence suggests that CHF-related illness and death in this group is significant enough to argue for earlier consideration of liver transplantation rather than waiting for a life-threatening complication to force the issue.26American Journal of Transplantation. Morbidity from Congenital Hepatic Fibrosis after Renal Transplantation for Autosomal Recessive Polycystic Kidney Disease
Prenatal Detection and Genetic Counseling
Because CHF most commonly arises in the context of ARPKD, prenatal imaging sometimes picks up signs before birth. In a study of fetuses with Caroli disease (which overlaps heavily with CHF), prenatal ultrasound revealed dilated bile ducts inside the liver and abnormal-appearing kidneys, including enlargement and increased brightness on imaging. Fetal MRI added further detail, showing a characteristic “central dot” sign in the liver that helped confirm the biliary abnormality.27Wiley Online Library (Prenatal Diagnosis). Prenatal Diagnosis of Caroli’s Disease by Ultrasound and MRI Imaging Prenatal detection opens the door for genetic counseling and delivery planning. Since CHF-related conditions are autosomal recessive, both parents must carry a copy of the mutant gene for a child to be affected, giving each pregnancy a one-in-four chance.
Genetic testing has become increasingly accessible, and for families with a known mutation, carrier testing and even preimplantation genetic diagnosis during in vitro fertilization are options. For families who have already had one affected child, these tools can meaningfully shape reproductive decisions.
Animal Models and the Search for Targeted Treatments
There is no drug that reverses or halts the fibrosis in CHF. Current treatment is entirely about managing complications. Researchers have recognized this gap and identified it as a critical unmet need, particularly the lack of pharmacological strategies to slow bile duct overgrowth and fibrosis progression in ciliopathies.28PubMed Central. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference
Much of the preclinical work relies on the PCK rat, an animal that carries a mutation in the Pkhd1 gene and develops both cystic kidneys and liver changes that closely resemble human CHF and Caroli disease.29PubMed Central. Polycystic kidney rat is a novel animal model of Caroli’s disease associated with congenital hepatic fibrosis Recent work using gene-expression profiling in these rats at multiple ages has begun to map out the molecular pathways that drive fibrosis over time, looking for intervention points that drugs could target.30PubMed Central. Global Transcriptomics of Congenital Hepatic Fibrosis in Autosomal Recessive Polycystic Kidney Disease using PCK rats The research is still early-stage, but having a good animal model that mirrors the human disease is a genuine advantage. Many rare diseases lack even that.
The rarity of CHF makes clinical trials difficult to organize. With only a few hundred documented cases worldwide, assembling enough patients for a randomized study is a logistical challenge that has slowed therapeutic development. International registries and natural-history studies are helping to build the kind of patient cohorts that will eventually make trials possible, but for now, families living with CHF are largely managing with the same tools that have been available for decades: endoscopy, surgical shunts, antibiotics for infections, and transplantation when all else falls short.